Aikedakan Particles Produce Effect On Vascular Endothelial Growth Factor Of The Medium-term Primary Liver Cancer Patients

Objective:By observing the Aikedakan particles on the medium-term liver vascular endothelial growth factor (VEGF) and to explore the mechanism of the treatment of primary liver cancer.Methods:The medium of primary liver cancer 60 patients were randomly divided into 2 groups,30 cases of Aikedakang treatment group,30 blank group, Aikedakang treatment group received Aikedakang granules and symptomatic treatment, control group symptomatic treatment alone. Observed before and after treatment in patients with symptoms, AFP, liver function, quality of life changes, and using double-antibody sandwich ELISA, serum vascular endothelial growth factor (VEGF) levels.Results:Compared with the control group, Aikedakang particles can improve symptoms and increase patient quality of life; with the control group and treatment group comparison with primary liver cancer Aikedakang particles can reduce serum vascular endothelial growth factor (VEGF) levels, and has a statistically significant (P<0.01).Conclusions:1. Aikedakang particles can improve primary liver cancer (PLC) in patients with symptoms and improve quality of life.2. Aikedakang particles can reduce the primary liver cancer (PLC) in patients with serum vascular endothelial growth factor (VEGF) levels, may inhibit tumor angiogenesis and play a role in cancer.